A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease

2026-525922-39-00 · tracked via the Priya Life Science EU tracker

Sponsor

Janssen Cilag International

Sponsor type

Pharmaceutical company

Therapeutic area

Immune System Diseases

Decision date

03/08/2026

Enrollment target

194

Sites

Norway, Romania, Austria, Italy, Slovakia, Germany, Hungary, Netherlands, Belgium, France, Portugal, Czechia, Poland, Spain, Greece

Condition studied

Moderately to Severely Active Crohn’s Disease

Investigational medicinal product(s)

JNJ-78934804Guselkumab

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Primary endpoint

Clinical remission at Week 48 Endoscopic remission at Week 48

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525922-39-00 on CTIS ↗ ← All trials in the EU